Clinical trial
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating…
NCT00470015 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00470015 |
|---|---|
| Title | Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma |
| Official title | Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MART-1 antigen, IL-2, gp100 antigen, GM-CSF, MART-1a peptide |
| Enrollment | 20 |
| Start date | Mar 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Jan 2, 2013 |
| First posted | May 7, 2007 |
| Last update posted | Feb 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: